TheraSphere™ Y-90 Therapy in Downstaging HCC to Liver Transplant
Dr. Sherrie Bhoori, Hepatologist from FOND. IRCCS IST. NAZ. DEI TUMORI - MILANO, underlines the role of TheraSphere™ Y-90 Therapy in downstaging strategies that enable liver transplantation for patients with hepatocellular carcinoma (HCC).
Speaking at ECIO 2025, she highlights how TheraSphere™ Y-90 Therapy has contributed to advancing multidisciplinary care, influencing patient eligibility for different pathways, and shaping long-term approaches for liver cancer care.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.